Lilly Reports Solid First-Quart...(organizations. Headquartered inIndianapo...)

Date:4/21/2008

organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com; Lilly's clinical trial registry is available at http://www.lillytrials.com.

F-LLY

This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company's results may also be affected by such factors as competitive developments affecting current products; rate of sales growth of recently launched products; the timing of anticipated regulatory approvals and launches of new products; regulatory actions regarding currently marketed products; other regulatory developments and government investigations; patent disputes and other litigation involving current and future products; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals; changes in tax law; asset impairments and restructuring charges; acquisitions and business development transactions; and the impact of exchange rates. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K filed February 2008. The company undertakes no duty to update forward-looking statements.

--------------------------------------------

Actos(R) (pioglitazone hydrochloride, Takeda)

AIR(R) (Alkermes, Inc.)

Alimta(R) (pemetrexed, Lilly
'/>"/>

SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related biology technology :

1. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
2. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
3. Lilly Announces Termination of AIR Insulin Program
4. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
7. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
8. Lilly Declares Fourth-Quarter Dividend
9. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
10. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
11. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook